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ABSTRACT
Background Smoking is the primary preventable risk 
factor for disease and premature mortality. It is highly 
addictive and cessation attempts are often unsuccessful. 
Incentive- based programmes may be an effective 
method to reach sustained abstinence. Individualisation 
of incentives based on personal characteristics yields 
potential to further increase the effectiveness of incentive- 
based programmes.
Method A randomised controlled trial among healthcare 
workers recruited through their employer and signed up 
for a group- based smoking cessation programme. The 
intervention under study is the provision of personalised 
incentives on validated smoking cessation at several 
time points after the smoking cessation programme. 
A total of 220 participants are required. Participants 
are randomised 1:1 into intervention (personalised 
incentives) or control (no incentives). All participants join 
the group- based programme. Incentives are provided on 
validated abstinence directly after the smoking cessation 
programme and after 3, 6 and 12 months.
Incentives are provided according to four schemes:
(1) Standard: total reward size €350, pay- out scheme: 
€50 (t=0), €50 (t=3 months), €50 (t=6 months) and 
€200 (t=12 months), (2) descending: total reward size 
€300, pay- out scheme: €150, €100, €50 and €0, (3) 
ascending: total reward size: €400, pay- out scheme: 
€0, €0, €50 and €350 and (4) deposit: total reward 
size €450, pay- out scheme: €50, €50, €150, €200; 
participants pay a €100 deposit, returned conditional on 
abstinence after 6 months.
Advice on which incentive scheme suits participants best 
is based on willingness to provide a deposit, readiness to 
quit, nicotine dependency and long- term or short- term 
reward preference. Participants are free to deviate from 
this advice. Abstinence is validated at each time point, 
with 15 months of total follow- up. The primary end point 
is validated abstinence at 12 months. Effectiveness will be 
determined by intention- to- treat analysis.
Ethics and dissemination The Erasmus MC Medical 
Ethics Committee decided that according to the Dutch 
Human Research Law (WMO), the protocol required no 
formal ethical approval. The results will be published in a 
peer- reviewed scientific journal and communicated to the 
participants.
Trial registration number Netherlands Trial Register 
NL7711.
BACKGROUND
Smoking is the primary preventable risk 
factor for disease and premature mortality.1 
Smoking is highly addictive and the vast 
majority of cessation attempts is unsuc-
cessful.2 In 2017, 38% of smokers in the 
Netherlands attempted to quit for at least 24 
hours.3 Several methods exist to increase the 
odds of quitting, such as nicotine replace-
ment therapy (NRT),4 individual behavioural 
counselling5 and group- based smoking cessa-
tion programmes.6 However, despite the 
relative effectiveness of these approaches, in 
absolute numbers, the proportion of smokers 
who quit is still low.
A promising method to encourage smoking 
cessation is the provision of financial 
Strengths and limitations of this study
 ► The PERSonalised Incentives for Supporting Tobacco 
cessation (PERSIST) trial has a unique hybrid design 
with a nudged choice embedded within a ran-
domised trial and is the first of its kind to provide 
a personalised advice on the mode of providing in-
centives, which likely best fits individual participant 
characteristics.
 ► This trial furthermore addresses a knowledge gap 
regarding long- term effectiveness of incentive- 
based strategies beyond the actual intervention 
period.
 ► A focus on helping hospital employees quit smoking 
is essential given their exemplary role in promoting 
health.
 ► For logistical reasons, participants from the inter-
vention and control arms may attend the same group 
sessions, potentially leading to spill- over effects.
 ► Due to the predicted sample size, it is not possible to 
include an additional intervention arm where incen-
tives are provided but not personalised.
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incentives upon validated abstinence. A recent Cochrane 
review found high- certainty evidence for increased 
smoking cessation rates at 6 or 12 months follow- up (risk 
ratio (RR)=1.49, 95% CI 1.28 to 1.73).7 Financial incen-
tives make the desired behaviour—in this case smoking 
cessation—more attractive by rewarding it. Importantly, 
financial incentives provide a short- term reward for a 
behavioural change that would normally only provide 
rewards in the long term. Long- term rewards are often 
valued less compared with short- term rewards due to 
declining perceived values of a delayed reward, so- called 
delay discounting.8 Typically, people give disproportion-
ally stronger relative weights to instantaneous rewards, 
so- called present bias,9 which gives a strong theoretical 
argument for providing short- term incentives for smoking 
cessation.
Incentive- based smoking cessation programmes have 
previously been implemented at the workplace.10–12 
Recently, the ‘Continuous Abstinence Through Corpo-
rate Healthcare’ (CATCH) trial was carried out among 
61 Dutch companies, randomising companies to group- 
based smoking cessation training for smoking employees 
with or without financial incentives to promote sustained 
cessation. Among those eligible to receive incentives (up 
to €350), the proportion of abstinent participants at 
1- year follow- up was significantly higher compared with 
those assigned to group- based training alone (41% vs 
26%).13
The effectiveness of incentives in promoting sustained 
smoking cessation depends on how and when rewards 
are provided. Traditionally, incentives have been tested 
according to a one- size- fits- all approach, using incentive 
size as a measure of anticipated effectiveness. A recent 
US trial comparing four different incentive programmes, 
however, showed that effectiveness is variable among 
different types and schemes of incentives.10 A deposit- 
based scheme, where participants commit their own 
money and return is conditional on validated abstinence, 
was unpopular but resulted in a significantly higher 
proportion of abstinent individuals compared with the 
reward- based incentive arm.10 Further analysis revealed 
associations between personal characteristics and accept-
ability and efficacy of incentive programmes.14 Both 
readiness- to- quit- smoking and low tendency to discount 
rewards were associated with increased effectiveness of 
both reward- based and deposit- based programmes. This 
suggests that personalisation of incentive programmes 
yields the potential to further increase the effectiveness 
of incentives to promote long- term abstinence.
Here we present the study protocol for the ‘Personalised 
Incentives for Supporting Tobacco Cessation’ (PERSIST) 
trial. The trial will be conducted among healthcare 
employees, for whom smoking cessation is particularly 
relevant as they may be expected to have an exemplary 
role. Moreover, in an attempt to work towards a smoke- 
free generation by 2040, the Dutch National Prevention 
Agreement requires university hospitals to be smoke free 
by mid-2020 and all healthcare facilities by 2025.
The aim of this study is to investigate whether person-
alised incentives in addition to a group- based smoking 
cessation programme will increase sustained smoking 
cessation among participants. This unique randomised 
controlled trial attempts to optimise the effectiveness of 
incentive programmes by providing personalised advice 
while leaving participants in full control to choose the 
incentive scheme of their choice. Our approach will 
further provide insight into which incentive scheme 
participants prefer and whether they can be nudged into 
the programme that most likely fits their personal charac-
teristics best.
METHODS AND ANALYSIS
Objectives
The main objective is to evaluate the effectiveness of 
personalised incentives in combination with group- based 
training sessions provided in the work environment on 
sustained smoking abstinence among healthcare workers 
compared with group- based training sessions alone.
Methods
The protocol follows the ‘Standard Protocol Items: 
Recommendations for Interventional Trials’ (SPIRIT) 
guidelines.15
Trial design
The PERSIST trial is a randomised controlled non- 
blinded trial with two parallel arms.
Study setting
The trial will be implemented at Dutch healthcare institu-
tions. The trial is primarily implemented at the Erasmus 
MC and is further being extended to Franciscus Gast-
huis & Vlietland and Ikazia Hospital. Inclusion of other 
healthcare institutions in the greater Rotterdam area is 
ongoing.
Trial population and eligibility criteria
Employees are eligible if they are (1) aged 18 years or 
more, (2) employed at one of the participating health-
care institutions and (3) a daily smoker (ie, smoking at 
least one cigarette per day). Exclusion criteria are (1) 
only using e- cigarettes and (2) not being able to physi-
cally attend the group- based training sessions.
Participants are recruited through their employer. 
Information about the training and the PERSIST trial is 
spread through intranet, email, flyers and screensavers. 
In collaboration with the organisation responsible for the 
training (SineFuma, see the Interventions section), infor-
mation sessions about the training and trial are organised.
Interventions
Eligible participants are individually randomised 1:1 
into a control arm, receiving no incentives, and an 
intervention arm, receiving personalised incentives. 
See figure 1 for a flowchart. Both arms participate in 
a group- based smoking cessation training provided 
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by SineFuma, a company specialised in supporting 
smoking cessation ( www. rookvrijookjij. nl). Groups 
consist of 8–16 participants and the training consists of 
seven sessions of approximately 90 min duration held 
over a period of 8 weeks. Participants in the interven-
tion and control arms participate in the same training 
sessions for logistical reasons. Group- based training 
sessions will start as soon as at least eight people have 
signed up to avoid participants lose motivation due to 
long waiting times.
Group sessions are provided at locations within each of 
the participating healthcare institutions. The aim of the 
training is to quit smoking as a group: participants jointly 
quit smoking in the third session. The follow- on sessions 
then focus on supporting sustained cessation through 
the first few weeks following the quit attempt. The partic-
ipants and coach discuss various types of NRT as part of 
the training. No NRT is provided in the trial but partic-
ipants are free to use an NRT of their choice. During 
each session, exhaled carbon monoxide (CO) measure-
ments (see the Outcomes section for more information) 
are used as a motivator to stay abstinent. The SineFuma 
group- based training is recognised as an efficient lifestyle 
intervention by the Dutch Government,16 and participa-
tion costs are reimbursed by basic insurance. As such, the 
control arm can be considered as usual care. If a portion 
of the costs are at the employee’s own expense through 
the deductible, employers have agreed to pay for the 
training.
Incentives
The difference between intervention and control condi-
tions lies within the provision of incentives. Participants 
in the intervention arm who remain continuously absti-
nent following the joint quit attempt are eligible to 
receive incentives according to a fixed time schedule. 
Incentives are provided as vouchers representing mone-
tary value. Vouchers can be spent at online web shops or 
on events such as a high tea in a local café or a night at 
a hotel and so on. Vouchers cannot be spent on tobacco 
products. The first incentive is provided directly after the 
group- based smoking cessation training, marking the 
moment from which participants have to remain absti-
nent independently.
In order to personalise incentives, four different incen-
tive schemes are offered, which participants are free to 
choose from. Across the different schemes, the monetary 
value of the incentives varies over time, and the potential 
total financial reward differs. The schemes are as follows 
(see figure 1):
1. The standard scheme. Analogous to the CATCH tri-
al,13 vouchers with a monetary value of €50, €50, €50 
and €200 are offered on validated abstinence at t=0 
month (ie, directly following the final smoking ces-
sation training session), t=3 months, t=6 months and 
t=12 months, respectively. Hence, the maximum total 
amount of incentives that can be earned is €350.
2. The descending scheme. Offer vouchers with a mon-
etary value of €150, €100 and €50 on validated ab-
Figure 1 Flow diagram of participant inclusion plus outline of control and intervention conditions. *Participants are provided 
with an informed choice regarding the individualised incentive scheme based on: 1. Degree of tobacco dependence, 2. 
Readiness to quit and 3. Present- bias. Note: red arrows are conditional on sustained biochemically validated smoking 
cessation.
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stinence at t=0 month, t=3 months and t=6 months, 
respectively. No further incentives are provided at t=12 
months. The maximum total amount of incentives is 
€300.
3. The ascending scheme. Offer vouchers with a mone-
tary value of €50 and €350 on validated abstinence t=6 
months and t=12 months, respectively. No incentives 
are provided at t=0 and t=3 months. The maximum to-
tal amount of incentives is €400.
4. The deposit- based scheme. Participants are asked to 
provide a €100 deposit at the beginning of the trial. 
The deposit scheme offers vouchers with a monetary 
value of €50 on validated abstinence at both t=0 and 
t=3 months. On validated abstinence at t=6 months, 
participants in this scheme will receive vouchers rep-
resenting a monetary value of €150; in addition, 
their €100 deposit will be refunded. On validated 
abstinence, at t=12 months they will receive vouchers 
representing a monetary value of €200. Accordingly, 
the maximum total amount of incentives is €450, ex-
cluding the deposit refund. If one does not stay ab-
stinent until 6 months after the last training session, 
the deposit will be donated to the Netherlands Lung 
Foundation.
In choosing the monetary amounts of incentives, we 
followed the general principle that the incentives should 
be large enough to motivate smoking cessation, but not 
too large either to avoid crowding out intrinsic motiva-
tion and to make scaling- up the trial prohibitively costly.17 
The standard scheme is identical to the scheme in the 
CATCH trial.18 Given time discounting due to inflation 
and individual impatience, it seems natural to apply 
some compensation in the total potential gains to the 
descending and ascending schemes. For example, why 
would someone self- select into an ascending scheme with 
zero pay- out in the first 6 months if the total potential 
gain is the same as the descending scheme where one 
can cash- in €150—already after at baseline? Further, as 
deposit contracts have proven to be most effective among 
those who choose one,10 we aimed to make this scheme 
the most attractive by providing the largest total reward 
size.
The key aspect of the intervention is the personali-
sation of the incentives. The varying values over time 
and varying total reward sizes allow for differences in 
reward preferences. For example, those who prefer to 
earn money sooner can choose accordingly (descending 
scheme), however, in that case the maximum total amount 
rewarded will be lower, while patience is rewarded with a 
higher total amount (ascending scheme). Halpern et al10 
showed that in the context of smoking cessation promo-
tion at the workplace, deposit schemes are unpopular but 
very effective; therefore, the current deposit scheme is 
designed to be the most attractive by having the largest 
potential total reward.
In an attempt to maximise the effectiveness of incen-
tive provision, participants receive automated advice 
regarding which scheme is most likely to fit their personal 
characteristics. This advice will be based on the following 
characteristics:
1. Degree of tobacco dependence. Based on the 
Fagerström Test for Nicotine Dependence.19 
Fagerström score below 5=no/low nicotine depen-
dence or Fagerström score of 5 or higher=nicotine 
dependent.
2. Readiness- to- quit. Based on Prochaska Stage of 
Change.20 Preparation stage (readiness to quit within 
the next 30 days) or (pre)contemplation stage (ready 
to quit within the next 6 months or not ready to quit 
at all).10 20
3. Present bias. Measured by temporal discounting mag-
nitude based on the Kirby Scale.21 Temporal discount-
ing refers to the phenomenon where future rewards 
are perceived as being worth less than an immediate 
reward.21 Based on a 27- item monetary choice ques-
tionnaire, those choosing more than 50% of the times 
the larger delayed rewards are classified as having de-
layed reward preference and those choosing less than 
50% of the times the larger delayed rewards are classi-
fied as having present reward preference.21 22
4. Willingness to pay a deposit, yes or no.
The first three factors have been associated with the 
effectiveness of smoking cessation interventions and 
with reaching sustained abstinence in reward- based 
programmes.14 The fourth factor is used as an indicator 
of acceptability of the deposit- based scheme, as deposit 
schemes are expected to be not only the most effective 
but also the least popular. The four factors are dichoto-
mised into ‘positive’ or ‘negative’ values in order to advise 
participants. Positive values are associated with higher 
quit percentages, that is, being in a preparation stage, 
having low nicotine dependence and having a delayed 
reward preference. Negative values are associated with 
lower quit percentages, that is, being in a (pre)contem-
plation stage, being nicotine dependent and having an 
immediate reward preference.
A combination of three positive values leads to the 
ascending scheme, two positive values to the standard 
scheme and two or three negative values to the descending 
scheme (see table 1). Those willing to pay a deposit are 
automatically advised the deposit- based scheme. The 
rationale behind this is that those with the lowest scores 
are likely to experience the most trouble quitting, and 
hence arguably benefit most from higher rewards in the 
beginning. Those with a higher score might rather benefit 
from incentives as a motivator to remain abstinent, and 
thus receive higher rewards towards the end of the study 
period. Importantly, participants are, however, free to 
choose the scheme of their preference when entering the 
trial regardless of the advice they received.
As participants have freedom of choice over the incen-
tive schemes, this is likely to result in a skewed distribu-
tion of participants over the schemes. However, this is not 
an issue in the current trial as the aim is to estimate the 
overall effect of personalised incentives compared with no 
incentives and not to estimate the discrete effects of the 
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individual schemes. In fact, the current trial will provide 
information as to which schemes are most popular, how 
this relates to personal characteristics and whether partic-
ipants may be nudged into the scheme that is assumed to 
best fit their personal characteristics.
Outcomes
The primary outcome is CO- validated 12- month contin-
uous abstinence from smoking (Russel’s Standard, 
RS12).23 The primary outcome is measured at t=12 months 
after the last group- based training. However, participants 
jointly quit smoking at the third training session which is 
approximately 1 month prior to the last training session. 
This 1- month gap between the joint smoking attempt 
and the start of our measurement allows participants to 
have a setback in smoking cessation while they are still in 
the training. From the end of the training (t=0 month) 
onwards, all participants are expected to be smoke free. 
Abstinence is assessed via self- reported abstinence and 
biochemically validated using expired air (CO) measure-
ments. Self- reported abstinence assesses both point and 
continuous abstinence. Point prevalence is assessed by 
7- day abstinence at each follow- up point and prolonged 
abstinence via the total continuous abstinence period.23 
Self- reported abstinence is validated via assessment of 
expired air CO concentrations using a handheld monitor 
(PiCO Smokerlyzer, Bedfont Scientific, Kent, England). 
An exhaled- air CO reading of <10 ppm is considered 
indicative of abstinence.23 CO quantification is a reliable 
and non- invasive method to ascertain recent smoking and 
the preferred method in populations using NRT.23 In case 
of disagreement between self- reported abstinence and 
CO reading, abstinence is defined by the latter.
Secondary outcomes are smoking abstinence directly 
after the group- based smoking cessation training (t=0), 
and after 3 months (t=3), after 6 months (t=6) and after 
15 months (t=15). The same methods and definitions 
to determine continuous abstinence are used for all 
outcomes.
Tertiary outcomes are the incremental cost- effectiveness 
ratio and the incremental cost- utility ratio, where the first 
is calculated using the total costs per quitter and the latter 
by the costs and self- reported quality of life (EurQol Five 
Dimensions).
Sample size
The CATCH trial, which employed similar incentive 
schemes as the standard arm of the current trial, reported 
41.1% abstinence at 12- month follow- up in the inter-
vention arm versus 26.4% among participants who only 
attended the training sessions.13 The PERSIST trial will 
be embedded in healthcare institutions, many of which 
are currently implementing smoke- free policies, which 
is expected to be an extra external motivator for cessa-
tion. As such the validated abstinence percentages are 
expected to be slightly higher than in the CATCH trial, 
that is, 45% and 30%, respectively. We expect that person-
alisation of the incentives will further increase effec-
tiveness to approximately 50%. In order to detect this 
difference in validated sustained abstinence (ie, 50% vs 
30%) with a power of 0.8 and an alpha of 0.05 and using 
1:1 randomisation, a total of at least 186 participants are 
Table 1 Answer combinations and advised schemes
Degree of tobacco 
dependence* Readiness- to- quit† Present bias‡
Willing to pay 
a deposit Scheme advice
<5 Ready to quit within the next 30 
days
Delayed reward 
preference
No Ascending
<5 Ready to quit within the next 30 
days
Present reward 
preference
No Standard
<5 Ready to quit in the next 6 
months or not ready to quit
Delayed reward 
preference
No Standard
<5 Ready to quit in the next 6 
months or not ready to quit
Present reward 
preference
No Descending
≥5 Ready to quit within the next 30 
days
Delayed reward 
preference
No Standard
≥5 Ready to quit within the next 30 
days
Present reward 
preference
No Descending
≥5 Ready to quit in the next 6 
months or not ready to quit
Delayed reward 
preference
No Descending
≥5 Ready to quit in the next 6 
months or not ready to quit
Present reward 
preference
No Descending
Any answer Any answer Any answer Yes Deposit
*Assessed via Fagerström score.
†Assessed via Prochaska state of change.
‡Assessed via Kirby discontinuity score.
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needed. Taking into account a 15% loss to follow- up due 
to unexpected employee turnover,11 24 220 participants 
are required. Further taking into account the potential 
maximum deviation from a 1:1 allocation ratio which may 
arise due to the stratified block randomisation procedure 
used, the minimum sample size required will increase in 
proportion to the number of different hospitals included 
in the trial. As the trial aims to estimate the effect of 
personalised incentives compared with no incentives 
and not to estimate the effect of each individual scheme, 
skewed allocation among the schemes is not an issue and 
is therefore not accounted for in the required sample size.
Recruitment
Recruitment takes place at participating healthcare insti-
tutions, starting with Erasmus MC. Potential participants 
are informed about the group- based smoking cessation 
training sessions through internal websites, flyers, infor-
mation sessions provided by SineFuma or by referral 
through their company doctor. Potential participants 
receive a letter explaining the different incentive schemes 
and the research procedures. On enrolment, informed 
consent is required.
Allocation
Within participating institutions, participants will be 
individually randomised 1:1 to either the control or 
intervention arm. Permuted block randomisation with 
varying block sizes of four and six is used. There are 
two stratification factors: participating institution and 
readiness- to- quit (preparation or contemplation stage). 
A computer- generated allocation sequence was provided 
by ALEA randomisation service, in collaboration with the 
Erasmus MC Clinical Trial Centre. The block sizes will 
not be disclosed so as to ensure allocation concealment. 
ALEA will not release the randomisation result until the 
patient has been recruited into the trial and all baseline 
questionnaires have been completed. Participants are 
informed about their allocation by email. Inherent to the 
intervention and study design, participants and outcome 
assessors will not be blinded to allocation. Group session 
trainers will be blinded to allocation and data will be 
anonymised before analysis.
Collection methods
As described in the Outcomes section, self- reported absti-
nence will be validated using expired air CO concentration 
readings obtained via a handheld monitor. Participants will 
be invited to complete web- based questionnaires assessing 
self- reported quality of life (EurQol Five Dimensions Health 
Questionnaire),25 smoking abstinence self- efficacy (Smoking 
Abstinence Self- efficacy Questionnaire),26 perceived stress 
(Perceived Stress Scale)27 and self- reported smoking absti-
nence (point prevalence and continuous abstinence)23 at 
each time point during follow- up. At baseline, the following 
items will be collected: educational level following the Inter-
national Standard Classification of Education (ISCED;28 0 
(early childhood education) to 8 (doctoral or equivalent 
level)), individual gross monthly income (<€1500, €1500–
1900, €1900–2600, >€2600), age, body mass index, gender 
and smoking behaviour (pack years, history of quit attempts 
and smoking history). In order to provide a personalised 
advise, the following questionnaires are also taken at base-
line: nicotine dependency (Fagerström Scale),19 readiness- 
to- quit (Prochaska Stages of Change)20 and present bias 
(Kirby Discontinuity Scale).21 29 See table 2 for a schematic 
overview of data collection during the trial.
Participants will be sent reminders after 5 days for uncom-
pleted questionnaires. A follow- up reminder will be sent 2 
Table 2 Schematic overview of data collection during the trial
Questionnaire Baseline t=0 month t=3 months t=6 months t=12 months* t=15 months
Demographic variables X           
Fagerström Scale X           
Prochaska Stage of Change X           
Kirby Discontinuity Scale X           
Willingness to pay a deposit X           
EQ- 5DF† X X X X X X
SASEQ‡ X X X X X X
Perceived Stress Scale X X X X X X
Self- reported abstinence§ X X X X X X
Evaluation training sessions   X         
Evaluation PERSIST           X
*t = 12 months is the primary endpoint.
†EurQol Five Dimensions Health Questionnaire.
‡Smoking Abstinence Self- efficacy Questionnaire.
§The self- reported abstinence questionnaire is adjusted to each corresponding time moment, for example, at t =3 the maximum period 
not smoked is 3 months and so on.
PERSIST, Personalised Incentives for Supporting Tobacco Cessation.
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days later. If there are still open items, participants will be 
contacted by telephone 2 days after the last reminder and a 
follow- up phone call will be made another 2 days later.
Data management
Informed consent will be provided digitally through Lime-
Survey (LimeSurvey GmbH, Hamburg, Germany). All 
trial data will be entered electronically using GemsTracker 
(GemsTracker, Erasmus MC and Equipe Zorgbedrijven, 
Rotterdam, The Netherlands). Data are handled confi-
dentially and stored anonymously, where data need to be 
linked to an individual subject (eg, linking longitudinal 
data), a subject identification code will be used. The code 
will not be based on patient initials and date of birth to 
preserve anonymity. The key to the code will be safe-
guarded by the investigator and kept separate from data 
files. All of the study essential documents will be retained 
and archived for 15 years after completion of the study. 
They will be stored securely and adequately protected 
from damage.
Statistical methods
The primary analysis compares continuous smoking absti-
nence rates at 12 months after the group- based training 
session in the intervention arm against the control arm, 
following an intention- to- treat analysis. In secondary analyses, 
continuous smoking abstinence at 15 months is assessed to 
see if abstinence is sustained after the incentives stopped. All 
randomised participants will be included in the final analysis, 
those lost to follow- up will be classified as smoking except 
for an unavoidable loss to follow- up (eg, untraceable contact 
information or death, following the RS12).23 Generalised 
linear models with a logit link function will be used to assess 
the difference in the primary outcome between control and 
intervention arms at t=12 months and to account for clus-
tering between hospitals.
Additionally, subgroup analyses will be performed to iden-
tify possible subgroup- specific effects of the intervention. 
Planned subgroup analyses are based on:
1. Readiness- to- quit. Preparation stage versus contempla-
tion stage.10 20
2. Degree of tobacco dependence. Fagerström score be-
low 5 versus Fagerström score of 5 or higher.19
3. Present bias. Delayed versus present reward preference. 
Delayed reward preference=more than 50% larger de-
layed reward is chosen or present reward preference=-
less than 50% larger delayed reward is chosen.21 22
4. Income. Based on gross monthly income in €. 
Low income=below 1500 versus moderate/high in-
come=above 1500.30
5. Educational level. Based on the ISCED.28 Lower edu-
cated=ISCED 0–4 versus higher educated=ISCED 5–8.
Subgroup analysis is not included in the power analysis and 
therefore exploratory. For missing data on subgroup infor-
mation, multiple imputations will be performed.
Patient and public involvement
Participants were not involved in designing the trial. Once 
the results are published, participants will be informed about 
the publication by email. This email will be drafted suitable 
for a non- specialist audience. Public involvement will be 
sought through the Erasmus Initiative Smarter Choices for 
Better Health initiative.
ETHICS AND DISSEMINATION
The study protocol has been assessed by the Erasmus Univer-
sity Medical Centre Medical Ethics Committee (MEC-2019-
0140). The committee decided that according to the Dutch 
Human Research Law (WMO), the protocol required no 
formal ethical approval. All participants will provide informed 
consent for participating in the study.
The results will be published in a peer- reviewed scientific 
journal. On completion of the trial and after the publica-
tion of the results, data requests can be submitted to the 
corresponding author at Erasmus MC, Rotterdam, The 
Netherlands.
DISCUSSION
We present the protocol of the PERSIST trial. The aim of 
the trial is to evaluate the effectiveness of personalised incen-
tives in addition to group- based smoking cessation training 
on sustained smoking abstinence among hospital employees 
compared with group- based training alone. Personalisation 
entails that participants are advised and can choose from four 
different incentive schemes: standard, ascending, descending 
and deposit- based.
Strengths and limitations
The PERSIST trial is unique in its approach to personal-
ising incentives to promote smoking cessation. Strong links 
between personal characteristics and effectiveness of incen-
tives to promote smoking cessation have been demonstrated 
previously, however, to our knowledge, the effectiveness 
of personalised incentives has not been studied before.14 
Another unique element of the PERSIST trial is that partic-
ipants receive personalised advice for an incentive scheme, 
based on personal characteristics, yet are free to deviate 
from the advised scheme. Voluntary choice with a person-
alised default is a common tool in behavioural economics to 
nudge people towards the scheme that is plausibly in their 
best interest.31 This feature is scientifically innovative in the 
context of smoking cessation programmes and importantly 
lets the treated individuals choose the scheme they will be 
enrolled.
By focusing on supporting smoking cessation among 
hospital employees, the PERSIST trial is executed in a highly 
relevant setting, as in light of the National Prevention Agree-
ment, all university hospitals have to be smoke free by 2020 
and all general hospitals by 2025.32 Finally, the PERSIST trial 
progresses from previous studies by extending follow- up 
beyond the last time point when incentives are provided to 
investigate if participants remain abstinent when incentives 
are no longer provided.
A limitation of the PERSIST trial is that participants from 
the intervention and control arm attend the same cessation 
support training sessions due to practical reasons, as slow 
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inclusion rates otherwise would have caused long waiting 
periods between signing up and starting the training. Partic-
ipants in the control arm might perceive this negatively and 
potentially drop out, causing attrition bias. Another conse-
quence could be spill- over effects33; sharing of vouchers 
between control and intervention arm, leading to a double 
underestimation of treatment effectiveness. To avoid this, 
participants are informed about their status as early as 
possible to make sure they have time to accept their status. 
A third arm consisting of non- personalised incentives could 
have provided additional potentially valuable information on 
the effectiveness of personalised incentives versus incentives 
provided according to a fixed scheme. However, this option 
would have required an unfeasibly large sample size.
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